Back to Search Start Over

Tumor subtypes and signature model construction based on chromatin regulators for better prediction of prognosis in uveal melanoma

Authors :
Yue Li
Chao Xiong
Li Li Wu
Bo Yuan Zhang
Sha Wu
Yu Fen Chen
Qi Hua Xu
Hong Fei Liao
Source :
Pathology and Oncology Research, Vol 29 (2023)
Publication Year :
2023
Publisher :
Frontiers Media S.A., 2023.

Abstract

Background: Uveal Melanoma (UM) is the most prevalent primary intraocular malignancy in adults. This study assessed the importance of chromatin regulators (CRs) in UM and developed a model to predict UM prognosis.Methods: Gene expression data and clinical information for UM were obtained from public databases. Samples were typed according to the gene expression of CRs associated with UM prognosis. The prognostic key genes were further screened by the protein interaction network, and the risk model was to predict UM prognosis using the least absolute shrinkage and selection operator (LASSO) regression analysis and performed a test of the risk mode. In addition, we performed gene set variation analysis, tumor microenvironment, and tumor immune analysis between subtypes and risk groups to explore the mechanisms influencing the development of UM.Results: We constructed a signature model consisting of three CRs (RUVBL1, SIRT3, and SMARCD3), which was shown to be accurate, and valid for predicting prognostic outcomes in UM. Higher immune cell infiltration in poor prognostic subtypes and risk groups. The Tumor immune analysis and Tumor Immune Dysfunction and Exclusion (TIDE) score provided a basis for clinical immunotherapy in UM.Conclusion: The risk model has prognostic value for UM survival and provides new insights into the treatment of UM.

Details

Language :
English
ISSN :
15322807
Volume :
29
Database :
Directory of Open Access Journals
Journal :
Pathology and Oncology Research
Publication Type :
Academic Journal
Accession number :
edsdoj.32001ba60fb84a7b83ba7a524239f9d0
Document Type :
article
Full Text :
https://doi.org/10.3389/pore.2023.1610980